| Name | Title | Contact Details |
|---|
The future of medical image management is in the cloud. Unfortunately, the farther data travels the more lag time accrues. We call this latency. Radiologists and other physicians are accustomed to receiving images at rates of 50 frames per second. When traveling across the entire United States, it may drop to 10 frames per second - much too slow for acceptable patient care. NucleusHealth™ overcomes latency via our patent-pending streaming protocols, client-side rendering techniques, modern web browser technologies, and the computing horsepower of todays phones, laptops and desktops. Diagnostic quality images come to life on displays at blazing-fast speeds. Even large file types such as digital breast tomosynthesis can be displayed in seconds, not minutes. With that single achievement, NucleusHealth sets a new standard for performance, scalability, security, high availability and response times. Faster, more accurate care means better outcomes at a lower cost. The next generation of medical image management has been born.
Conkerexe Biosciences is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
San Diego Home Health Care is a Encinitas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
S Epilepsy is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible. PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb®. NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways. NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns. We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.